ClinicalTrials.gg
CompletedNCT01275196Updated Apr 8, 2016Results posted

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

A Phase 3 interventional study of Nilotinib and Imatinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
7th of 66
267 · median 55
Started
2011
with 3 others
Phase 3
15 of 66
none open now
Registered
27th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 7th largest by enrollment, is one of 4 that started in 2011, is one of 15 in phase 3, and was the 27th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • Newly diagnosed,
  • Ph+ chronic myeloid leukemia,
  • CML-CP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of Chinese ethnicity greater than or equal to 18 years of age
  • 0, 1, or 2.
  • Patients with CML-CP (Ph+) within 6 months of diagnosis (date of initial diagnosis is the date of first cytogenetic analysis). Standard conventional cytogenetic analysis must be done on bone marrow. (FISH cannot be used)
  • Diagnosis of chronic myelogenous leukemia in chronic phase with cytogenetic confirmation for the presence of Philadelphia chromosome of (9;22 translocation; less than 20 metaphases may be used for diagnosis
  • Documented chronic phase CML will meet all the criteria defined by:

    • \< 15% blasts in peripheral blood and bone marrow
    • \< 30% blasts plus promyelocytes in peripheral blood and bone marrow
    • \< 20% basophils in the peripheral blood
    • ≥ 100 x 109/L (≥ 100,000/mm3)
  • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
  • Adequate organ function as defined by:

    • Total \< 1.5 x
    • and SGPT \< 2.5 x ULN
    • Creatinine \< 1.5 x ULN
    • Serum amylase and lipase ≤ 1.5 x ULN
    • Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.
  • Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):

    • Potassium ≥ LLN
    • Magnesium ≥ LLN
    • Phosphate ≥ LLN
    • Total calcium (corrected for serum albumin) ≥ LLN.
  • Ability to provide written prior to any study related screening procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Patients with previously documented T315I mutations;
  • Treatment with tyrosine kinase inhibitor(s) prior to study entry is not allowed, except in the following situation: in emergent cases where the patient requires disease management while awaiting study start, commercial supplies of Gleevec/Glivec at any dose may be prescribed to the patient but for no longer than 2 weeks in duration.
  • Treatment with IFN for more than 3 months.
  • Impaired cardiac function including any one of the following:
  • Complete left bundle branch block
  • Long syndrome or a known family history of long QT syndrome.
  • History of or presence of ventricular or atrial tachyarrhythmias
  • Clinically significant resting bradycardia (\<50 beats per minute)
  • QTc > 450 msec If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
  • History of clinically documented myocardial infarction within past 12 months
  • History of unstable angina (during the last 12 months)
  • Other clinically significant heart disease (e.g., congestive heart failure or uncontrolled hypertension).
  • Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).
  • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
  • History of significant congenital or acquired bleeding disorder unrelated to cancer.
  • Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery.
  • Treatment with other agents (defined as not used in accordance with the approved indication) within 30 days of Day 1.
  • History of non-compliance to medical regimens or inability to grant consent.
  • Patients with another primary except if the other primary malignancy is neither currently clinically significant or requiring active intervention
  • Patients actively receiving therapy with strong inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm or reference Protocol post text appendix 1.
  • Patients actively receiving therapy with strong CYP3A4 inducers (e.g., dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John's Wort) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm or reference Protocol post text appendix 1.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.
  • Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease.
  • Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug (Please see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a comprehensive list of agents that prolong the QT interval).
  • Patients who are: (a) pregnant, (b) breast feeding, (c) of without a negative pregnancy test prior to baseline and (d) female of childbearing potential unwilling to use precautions throughout the trial ( women must be amenorrheic for at least 12 months to be considered of non-childbearing potential)

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Drug: Nilotinib

  • Active comparator
    Imatinib

    Drug: Imatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Major Molecular Response (MMR) at 12 Months - With Imputation.

    Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. This endpoint was calculated based on the 12 month analysis.

    Time frame: 12 months

Secondary outcomes

  1. MMR Rate at Each Time Point

    Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. These time points including the 12 month data were calculated based on the final analysis after the end of the study.

    Time frame: Months 3,6,9,12,15, 18, 21, 24, 36

  2. Best MMR by Each Timepoint

    Best MMR rates by scheduled time point are cumulative response rates up to that time point. In this analysis, patients who had achieved MMR at or before the time point were counted as responders, no matter if they lost the response/discontinued or not. Therefore, this response rate represented the best observed response rate up to that specific time point.

    Time frame: Months 3,6,9,12,15, 18, 21, 24, 36

  3. Kaplan-Meier Estimates of Time to First MMR

    Time to first MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375.

    Time frame: End of study (up to 40 months)

  4. Durable MMR Rate at 24 Months

    The rate of durable MMR at 24 months, defined as the proportion of patients who have achieved MMR at 12 months, and also maintain continuous MMR until the 24 month time point (1 month = 28 days) without intervening loss of MMR in between 12 and 24 months

    Time frame: 24 months

  5. Kaplan-Meier Estimates of Duration of First MMR Among Patients Who Achieved MMR

    Duration of first MMR (months) = (date of loss of MMR or censoring-date of first MMR + 1)/30.4375.

    Time frame: End of Study (Up to 40 months)

  6. Best Complete Cytogenic Response (CCyR) Rate by Each Time Point

    CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics.

    Time frame: Months 6, 12, 18, 30, 24, 36

  7. Kaplan-Meier Estimates of Time to First CCYR

    Time to first CCyR (months) = (date of first CCyR - date of randomization + 1) / 30.4375.

    Time frame: End of study (up to 40 months)

  8. Kaplan-Meier Estimates of Duration of First CCyR Among Patients Who Achieved CCyR

    Duration of CCyR (months) = (date of CCyR loss or censoring-date of first CCyR + 1)/30.4375

    Time frame: End of Study (up to 40 months)

  9. Kaplan-Meier Estimates of Time to Progression to Accelerated Phase/Blast Crisis (AP/BC) on Treatment

    Time to progression to AP/BC was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of CML-related death, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or CML-related deaths occurring on treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease, or cytogenetic evaluation) in the study for patients without event. * On-study: included progressions to AP/BC or CML-related deaths occurring in the study or during the follow-up period after discontinuation of treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment

    Time frame: End of study (up to 40 months)

  10. Kaplan-Meier Estimates of Event-free Survival (EFS) on Treatment

    Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following:-Death due to any cause, - Progression to AP or BC, Loss of partial cytogenetic response (PCyR), - Loss of CCyR, - Loss of CHR

    Time frame: End of Study (up to 40 months)

  11. Kaplan-Meier Estimates of Progression-free Survival (PFS) on Treatment

    Progression-free survival was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of death from any cause, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or deaths occurring only on-treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease or cytogenetic evaluation) in the study before the cut-off date of the analysis for patients without event. * On-study: included progressions to AP/BC or deaths occurring in the study or during the follow-up period after discontinuation of study treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment.

    Time frame: End of study (up to 40 months)

  12. Kaplan-Meier Estimates of Overall Survival (OS) on Treatment

    Patients who discontinued study treatment early or completed the study protocol and did not enter into the extension protocol were to be followed for survival every 3 months for up to 2 calendar years from the date the last patient randomized received the first dose of study drug and every 6 months until Last Patient Last Visit. Overall survival (all deaths) was defined as the time between date of randomization and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment, i.e. overall survival on-study. The time was censored at the date of last assessment in the study for patients who are still being treated and at the date of last contact for patients who discontinued treatment.

    Time frame: End of Study (up to 40 months)

  13. Best Complete Hematologic Response (CHR)

    CHR was defined as having all of the following criteria present at any assessment, which was confirmed by another assessment at least after 4 weeks: • WBC count \< 10 x 10E9 /L • Platelet count \< 450 x 10E9 /L • Basophils \< 5% • No blasts and promyelocytes in peripheral blood • Myelocytes + metamyelocytes \< 5 % in peripheral blood • No evidence of extramedullary involvement. The assessment was not considered CHR, if there were any values indicative of CML in AP or BC (i.e. by blasts in bone marrow). For confirmation of CHR, both the initial CHR as well as the confirming assessment (at least 4 weeks after the initial assessment) had to satisfy all criteria mentioned above, without any assessment in between which indicated 'No response'.

    Time frame: Months 1, 3, 4, 5, 6, 9,12, 15,18, 21, 24, 30, 36

  14. Modified ELN2009 Criteria

    Patients satisfying criteria for several "modified ELN 2009" categories are presented once under the worst category (Optimal\> Suboptimal \> Treatment failure). Patients in the "Discontinued" category are those who discontinued before the time point considered without satisfying any of the ELN 2009 criteria. Patients in the "Missing" category are those ongoing in the trial at the time point considered but with only missing or non evaluable data for ELN 2009 criteria.

    Time frame: End of Study (up to 40 months)

  15. Actual Dose Intensity

    Total dose/time on treatment (periods of zero dose were included).

    Time frame: End of Study (up to 40 months)

  16. Summary Statistics of Trough Imatinib and Major Metabolite CGP74588 of Imatinib and Nilotinib PK Concentration by Time Point

    Pharmacokinetic Analysis Set

    Time frame: 12 Months

07

Results

Posted Dec 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneImatinibNilotinib
Started133134
Intended to continue into extension112113
Completed113113
Not completed2021
Withdrew: Adverse event35
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up10
Withdrew: Disease progression65
Withdrew: Protocol violation10
Withdrew: Suboptimal response/treatment failure56

Outcome measures

PrimaryMajor Molecular Response (MMR) at 12 Months - With Imputation.

Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. This endpoint was calculated based on the 12 month analysis.

Time frame:
12 months
Reported as:
Number · Percentage of Participants
Major Molecular Response (MMR) at 12 Months - With Imputation.
Percentage of ParticipantsImatinibNilotinib
Major Molecular Response (MMR) at 12 Months - With Imputation.27.8 (20.4 to 36.3)52.2 (43.4 to 60.9)
Statistical analysis
  • Imatinib vs Nilotinib · Cochran-Mantel-Haenszel · p = 0.0001
SecondaryMMR Rate at Each Time Point

Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. These time points including the 12 month data were calculated based on the final analysis after the end of the study.

Time frame:
Months 3,6,9,12,15, 18, 21, 24, 36
Reported as:
Number · Percentage of Participants
MMR Rate at Each Time Point
Percentage of ParticipantsImatinibNilotinib
3 Months3.0 (0.8 to 7.5)13.4 (8.2 to 20.4)
6 Months18.0 (11.9 to 25.6)44.8 (36.2 to 53.6)
9 Months21.1 (14.5 to 29.0)47.8 (39.1 to 56.6)
12 Months27.8 (20.4 to 36.3)53.0 (44.2 to 61.7)
15 Months36.1 (27.9 to 44.9)59.0 (50.1 to 67.4)
18 Months40.6 (32.2 to 49.5)57.5 (48.6 to 66.0)
21 Months41.4 (32.9 to 50.2)61.9 (53.2 to 70.2)
24 Months49.6 (40.8 to 58.4)61.9 (53.2 to 70.2)
36 Months59.4 (50.5 to 67.8)68.7 (60.1 to 76.4)
SecondaryBest MMR by Each Timepoint

Best MMR rates by scheduled time point are cumulative response rates up to that time point. In this analysis, patients who had achieved MMR at or before the time point were counted as responders, no matter if they lost the response/discontinued or not. Therefore, this response rate represented the best observed response rate up to that specific time point.

Time frame:
Months 3,6,9,12,15, 18, 21, 24, 36
Reported as:
Number · Percentage of Participants
Best MMR by Each Timepoint
Percentage of ParticipantsImatinibNilotinib
Overall66.9 (58.2 to 74.8)73.9 (65.6 to 81.1)
Month 33.0 (0.8 to 7.5)13.4 (8.2 to 20.4)
Month 618.0 (11.9 to 25.6)45.5 (36.9 to 54.3)
Month 922.6 (15.8 to 30.6)51.5 (42.7 to 60.2)
Month 1230.8 (23.1 to 39.4)56.0 (47.1 to 64.5)
Month 1537.6 (29.3 to 46.4)62.7 (53.9 to 70.9)
Month 1842.9 (34.3 to 51.7)64.2 (55.4 to 72.3)
Month 2146.6 (37.9 to 55.5)66.4 (57.8 to 74.3)
Month 2452.6 (43.8 to 61.3)67.9 (59.3 to 75.7)
Month 3665.4 (56.7 to 73.4)73.9 (65.6 to 81.1)
SecondaryKaplan-Meier Estimates of Time to First MMR

Time to first MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375.

Time frame:
End of study (up to 40 months)
Reported as:
Median · months
Kaplan-Meier Estimates of Time to First MMR
monthsImatinibNilotinib
Kaplan-Meier Estimates of Time to First MMR21.7 (16.5 to 25.2)8.1 (5.6 to 11.1)
SecondaryDurable MMR Rate at 24 Months

The rate of durable MMR at 24 months, defined as the proportion of patients who have achieved MMR at 12 months, and also maintain continuous MMR until the 24 month time point (1 month = 28 days) without intervening loss of MMR in between 12 and 24 months

Time frame:
24 months
Reported as:
Number · Perentage of Participants
Durable MMR Rate at 24 Months
Perentage of ParticipantsImatinibNilotinib
Durable MMR Rate at 24 Months27.8 (20.4 to 36.3)50.7 (42.0 to 59.5)
SecondaryKaplan-Meier Estimates of Duration of First MMR Among Patients Who Achieved MMR

Duration of first MMR (months) = (date of loss of MMR or censoring-date of first MMR + 1)/30.4375.

Time frame:
End of Study (Up to 40 months)
Reported as:
Median · Months
Kaplan-Meier Estimates of Duration of First MMR Among Patients Who Achieved MMR
MonthsImatinibNilotinib
Kaplan-Meier Estimates of Duration of First MMR Among Patients Who Achieved MMRNA (NA to NA)NA (NA to NA)
SecondaryBest Complete Cytogenic Response (CCyR) Rate by Each Time Point

CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics.

Time frame:
Months 6, 12, 18, 30, 24, 36
Reported as:
Number · Percentage of Participants
Best Complete Cytogenic Response (CCyR) Rate by Each Time Point
Percentage of ParticipantsImatinibNilotinib
Overall89.5 (83.0 to 94.1)85.8 (78.7 to 91.2)
Month 657.1 (48.3 to 65.7)66.4 (57.8 to 74.3)
Month 1280.5 (72.7 to 86.8)77.6 (69.6 to 84.4)
Month 1884.2 (76.9 to 90.0)80.6 (72.9 to 86.9)
Month 3088.0 (81.2 to 93.0)84.3 (77.0 to 90.0)
Month 2486.5 (79.5 to 91.8)83.6 (76.2 to 89.4)
Month 3689.5 (83.0 to 94.1)85.8 (78.7 to 91.2)
SecondaryKaplan-Meier Estimates of Time to First CCYR

Time to first CCyR (months) = (date of first CCyR - date of randomization + 1) / 30.4375.

Time frame:
End of study (up to 40 months)
Reported as:
Median · months
Kaplan-Meier Estimates of Time to First CCYR
monthsImatinibNilotinib
Kaplan-Meier Estimates of Time to First CCYR6.1 (5.6 to 6.6)5.6 (5.6 to 6.2)
SecondaryKaplan-Meier Estimates of Duration of First CCyR Among Patients Who Achieved CCyR

Duration of CCyR (months) = (date of CCyR loss or censoring-date of first CCyR + 1)/30.4375

Time frame:
End of Study (up to 40 months)
Reported as:
Median · Months
Kaplan-Meier Estimates of Duration of First CCyR Among Patients Who Achieved CCyR
MonthsImatinibNilotinib
Kaplan-Meier Estimates of Duration of First CCyR Among Patients Who Achieved CCyRNA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimates of Time to Progression to Accelerated Phase/Blast Crisis (AP/BC) on Treatment

Time to progression to AP/BC was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of CML-related death, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or CML-related deaths occurring on treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease, or cytogenetic evaluation) in the study for patients without event. * On-study: included progressions to AP/BC or CML-related deaths occurring in the study or during the follow-up period after discontinuation of treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment

Time frame:
End of study (up to 40 months)
Reported as:
Median · Months
Kaplan-Meier Estimates of Time to Progression to Accelerated Phase/Blast Crisis (AP/BC) on Treatment
MonthsImatinibNilotinib
Kaplan-Meier Estimates of Time to Progression to Accelerated Phase/Blast Crisis (AP/BC) on TreatmentNA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimates of Event-free Survival (EFS) on Treatment

Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following:-Death due to any cause, - Progression to AP or BC, Loss of partial cytogenetic response (PCyR), - Loss of CCyR, - Loss of CHR

Time frame:
End of Study (up to 40 months)
Reported as:
Median · Months
Kaplan-Meier Estimates of Event-free Survival (EFS) on Treatment
MonthsImatinibNilotinib
Kaplan-Meier Estimates of Event-free Survival (EFS) on TreatmentNA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimates of Progression-free Survival (PFS) on Treatment

Progression-free survival was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of death from any cause, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or deaths occurring only on-treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease or cytogenetic evaluation) in the study before the cut-off date of the analysis for patients without event. * On-study: included progressions to AP/BC or deaths occurring in the study or during the follow-up period after discontinuation of study treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment.

Time frame:
End of study (up to 40 months)
Reported as:
Median · Months
Kaplan-Meier Estimates of Progression-free Survival (PFS) on Treatment
MonthsImatinibNilotinib
Kaplan-Meier Estimates of Progression-free Survival (PFS) on TreatmentNA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimates of Overall Survival (OS) on Treatment

Patients who discontinued study treatment early or completed the study protocol and did not enter into the extension protocol were to be followed for survival every 3 months for up to 2 calendar years from the date the last patient randomized received the first dose of study drug and every 6 months until Last Patient Last Visit. Overall survival (all deaths) was defined as the time between date of randomization and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment, i.e. overall survival on-study. The time was censored at the date of last assessment in the study for patients who are still being treated and at the date of last contact for patients who discontinued treatment.

Time frame:
End of Study (up to 40 months)
Reported as:
Median · Months
Kaplan-Meier Estimates of Overall Survival (OS) on Treatment
MonthsImatinibNilotinib
Kaplan-Meier Estimates of Overall Survival (OS) on TreatmentNA (NA to NA)NA (NA to NA)
SecondaryBest Complete Hematologic Response (CHR)

CHR was defined as having all of the following criteria present at any assessment, which was confirmed by another assessment at least after 4 weeks: • WBC count \< 10 x 10E9 /L • Platelet count \< 450 x 10E9 /L • Basophils \< 5% • No blasts and promyelocytes in peripheral blood • Myelocytes + metamyelocytes \< 5 % in peripheral blood • No evidence of extramedullary involvement. The assessment was not considered CHR, if there were any values indicative of CML in AP or BC (i.e. by blasts in bone marrow). For confirmation of CHR, both the initial CHR as well as the confirming assessment (at least 4 weeks after the initial assessment) had to satisfy all criteria mentioned above, without any assessment in between which indicated 'No response'.

Time frame:
Months 1, 3, 4, 5, 6, 9,12, 15,18, 21, 24, 30, 36
Reported as:
Number · Percentage of participants
Best Complete Hematologic Response (CHR)
Percentage of participantsImatinibNilotinib
Overall94.7 (89.5 to 97.9)94.8 (89.5 to 97.9)
Month 166.2 (57.5 to 74.1)73.1 (64.8 to 80.4)
Month 391.0 (84.8 to 95.3)91.8 (85.8 to 95.8)
Month 493.2 (87.5 to 96.9)93.3 (87.6 to 96.9)
Month 594.0 (88.5 to 97.4)93.3 (87.6 to 96.9)
Month 694.7 (89.5 to 97.9)93.3 (87.6 to 96.9)
Month 994.7 (89.5 to 97.9)93.3 (87.6 to 96.9)
Month 1294.7 (89.5 to 97.9)94.0 (88.6 to 97.4)
Month 1594.7 (89.5 to 97.9)94.0 (88.6 to 97.4)
Month 1894.7 (89.5 to 97.9)94.8 (89.5 to 97.9)
Month 2194.7 (89.5 to 97.9)94.8 (89.5 to 97.9)
Month 2494.7 (89.5 to 97.9)94.8 (89.5 to 97.9)
Month 3094.7 (89.5 to 97.9)94.8 (89.5 to 97.9)
Month 3694.7 (89.5 to 97.9)94.8 (89.5 to 97.9)
SecondaryModified ELN2009 Criteria

Patients satisfying criteria for several "modified ELN 2009" categories are presented once under the worst category (Optimal\> Suboptimal \> Treatment failure). Patients in the "Discontinued" category are those who discontinued before the time point considered without satisfying any of the ELN 2009 criteria. Patients in the "Missing" category are those ongoing in the trial at the time point considered but with only missing or non evaluable data for ELN 2009 criteria.

Time frame:
End of Study (up to 40 months)
Reported as:
Number · Percentage of Participants
Modified ELN2009 Criteria
Percentage of ParticipantsImatinibNilotinib
Optimal Response39.855.2
Suboptimal Response41.424.6
Treatment Failure16.514.9
Discontinued2.35.2
SecondaryActual Dose Intensity

Total dose/time on treatment (periods of zero dose were included).

Time frame:
End of Study (up to 40 months)
Reported as:
Mean · mg/day
Actual Dose Intensity
mg/dayImatinibNilotinib
Actual Dose Intensity416.0 ± 62.40536.4 ± 99.07
SecondarySummary Statistics of Trough Imatinib and Major Metabolite CGP74588 of Imatinib and Nilotinib PK Concentration by Time Point

Pharmacokinetic Analysis Set

Time frame:
12 Months
Reported as:
Mean · ng/mL
Summary Statistics of Trough Imatinib and Major Metabolite CGP74588 of Imatinib and Nilotinib PK Concentration by Time Point
ng/mLImatinibCGP74588Nilotinib
Day 8 (Cycle 1)1235.3 ± 632.36255.4 ± 154.741036.8 ± 618.10
Day 28 (Cycle 1)1291.3 ± 553.44288.9 ± 130.25970.4 ± 606.89
Day 84 (Cycle 3)1137.8 ± 461.50235.7 ± 104.311172.4 ± 656.25
Day 168 (Cycle 6)1078.2 ± 413.99243.2 ± 88.661154.8 ± 1034.15
Day 336 (Cycle 12)1111.1 ± 434.85238.7 ± 89.111370.5 ± 878.88
Average trough PK1188.7 ± 452.24258.7 ± 112.881137.4 ± 631.31

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib 400 mg qd—13/132 (9.8%)124/132 (93.9%)
Nilotinib 300 mg Bid—11/133 (8.3%)131/133 (98.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventImatinib 400 mg qdNilotinib 300 mg Bid
Bone marrow failureBlood and lymphatic system disorders1/1323/133
Platelet count decreasedInvestigations0/1323/133
GranulocytopeniaBlood and lymphatic system disorders1/1320/133
ThrombocytopeniaBlood and lymphatic system disorders1/1320/133
Thrombocytopenic purpuraBlood and lymphatic system disorders1/1320/133
ThrombocytosisBlood and lymphatic system disorders1/1320/133
Anal abscessInfections and infestations1/1320/133
Ankle fractureInjury, poisoning and procedural complications1/1320/133
Blast cell count increasedInvestigations1/1320/133
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1320/133
Most frequent other events
Showing 10 of 40
Most frequent other events
EventImatinib 400 mg qdNilotinib 300 mg Bid
RashSkin and subcutaneous tissue disorders17/13247/133
ThrombocytopeniaBlood and lymphatic system disorders37/13241/133
Blood bilirubin increasedInvestigations8/13241/133
HyperbilirubinaemiaHepatobiliary disorders4/13240/133
Lipase increasedInvestigations29/13237/133
LeukopeniaBlood and lymphatic system disorders35/13227/133
Platelet count decreasedInvestigations30/13223/133
White blood cell count decreasedInvestigations28/13216/133
Alanine aminotransferase increasedInvestigations16/13228/133
Eyelid oedemaEye disorders25/1324/133

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ImatinibNilotinibTotal
Mean39.7 ± 12.8641.5 ± 12.7640.6 ± 12.82
Sex: Female, Male
Sex: Female, Male(Participants)ImatinibNilotinibTotal
Female524395
Male8191172
08

Study locations

12 sites
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Beijing, 100044, China
  • Novartis Investigative Site
    Fuzhou, 350001, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Nan Jing, 210008, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200433, China
09

References and documents

Publications

  • Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015 Apr 30;125(18):2771-8. doi: 10.1182/blood-2014-09-601674. Epub 2015 Mar 12. PubMed 25766724 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2011
First posted
Jan 12, 2011
Start
Apr 2011
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Dec 9, 2015
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01275196
Responsible party
Sponsor
First posted
Jan 12, 2011
Start date
Apr 2011
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Dec 9, 2015
Last update
Apr 8, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion